Abstract 470P
Background
Glioblastoma multiforme (GBM) is the most common malignant brain tumor. MRPs are involved in mitochondrial translation, with previously revealed role in cancer. Here we aimed to understand their role in GBM.
Methods
Differentially expressed genes (DEGs) were identified through the ‘DESeq2' on R and GEO2R. Survival analysis with optimal expression cutoff for Overall Survival (OS) and median cutoffs for Disease-Free Survival (DFS) based on TCGA-GBM was done using the ‘survival' and 'survminer' R packages, and GEPIA2 online tool. Gene Set Enrichment Analysis (GSEA) was performed using Enrichr tool. miRNA-mRNA networks were constructed using MultiMiR and CytoScape. Immune and methylation analyses were conducted using TIMER2.0 (XCELL) and cBioPortal.
Results
OS estimates indicated worse survival in patients with higher expression of selected MRPs (Table). Further analysis indicated that elevated expression of MRPS33 and MRPL23 is correlated with decreased DFS, with Hazard Ratios (HRs) of 1.80 (p = 0.0012) and 1.70 (p = 0.0039), respectively. GSEA on upregulated genes in high MRPS33-expressers revealed relations to PDGF, NCAM1 interactions, EMT, and integrins in angiognesis. miRNA-mRNA network has identified hub miRNAs, like hsa-miR-1-3p, to have validated interactions with MRPs of interest. Expression of MRPL41, MRPL35, and MRPS33, had negative correlations with HM27/HM450 methylation (Spearman's rho = -0.41, -0.20, and -0.19, respectively; p < 0.05). Finally, there was a positive correlation between MRPS33 expression and Macrophage M2 infiltration in GBM (rho = 0.393, p < 0.05). Table: 470P
Selected MRPs gene expression and GBM patient survival, HR > 1 suggests a harmful effect of the gene on survival
Gene | HR | P Value | 95% CI | DE |
MRPL41 | 1.732784 | 0.0047 | (1.35, 2.11) | D |
MRPL32 | 1.946699 | 0.0010 | (1.55, 2.34) | U |
MRPL17 | 1.787801 | 0.0070 | (1.37, 2.21) | U |
MRPL23 | 1.689083 | 0.0103 | (1.29, 2.09) | U |
MRPS33 | 1.58498 | 0.0226 | (1.19, 1.98) | U |
DE: Differential expression (GBM relative to normal) across GSE4290, GSE68848, and TCGA-GBM (overlap); U: Upregulated; D: Downregulated.
Conclusions
Our study identified a complex multi-omic framework through which MRPs are regulated and play their prognostic and tumorigenic roles in GBM.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
556P - Predicting the efficacy of neoadjuvant chemoradiotherapy in rectal cancer patients based on dynamic tumor-informed ctDNA-MRD
Presenter: Weiwei Xiao
Session: Poster session 16
557P - Three-year update of real-world evaluation of ColonAiQ for colorectal cancer screening in asymptomatic individuals
Presenter: Baohua Wang
Session: Poster session 16
558P - Survival benefit of adjuvant chemotherapy based on molecular residual disease detection in resected colorectal liver metastases: Subgroup analysis from CIRCULATE-Japan GALAXY
Presenter: Kozo Kataoka
Session: Poster session 16
561P - Liquid biopsy tracking of immunotherapy-induced T cell dynamics in MSS colorectal and endometrial tumors
Presenter: Holger Heyn
Session: Poster session 16
562P - Acquired genomic alterations on first-line chemotherapy (CT) + cetuximab in advanced colorectal cancer (mCRC): Circulating tumor (ct)DNA analysis of the randomized phase II trial TIME-PRODIGE-28
Presenter: Valerie Boige
Session: Poster session 16
564P - Short-course radiotherapy combined with chemotherapy and PD-1 inhibitor in proficient mismatch repair or microsatellite stable (pMMR/MSS) low-lying early rectal cancer: Preliminary findings from a prospective, multi-center, phase II trial (TORCH-E)
Presenter: Fan Xia
Session: Poster session 16
565P - Neoadjuvant chemotherapy, excision, and observation for early rectal cancer: The phase II NEO trial (CCTG CO.28) results after minimum 3 years follow up
Presenter: Carl Brown
Session: Poster session 16